OpdivoYervoy – Health

Bristol Myers Squibb’s Opdivo-Yervoy combo helps mesothelioma patients live longer

Bristol-Myers Squibb’s Opdivo-Yervoy combo is awaiting some critical decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication, too. The immuno-oncology duo topped chemo at extending the lives of phase 3 trial patients with previously untreated malignant pleural mesothelioma (MPM), the company said Monday. The rare cancer,… Read More »

Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Bristol Myers Squibb’s Opdivo-Yervoy immuno-oncology combo has had some ups and downs lately. But it can now claim a new FDA nod in pretreated liver cancer. The Opdivo-Yervoy regimen is now FDA-approved to treat hepatocellular carcinoma patients who have previously received Bayer’s standard-of-care Nexavar, Bristol said Wednesday. Because the FDA doled out the indication under… Read More »